Abstract
American Joint Committee on Cancer (AJCC), TNM staging, represents the cornerstone of management for cutaneous melanoma. This staging system groups patients with similar prognoses and has important implications in optimizing management and treatment and conducting better clinical trials. T describes the extent of the primary tumor, N the extent of regional lymph node metastases, and M the extent of distant metastases. The AJCC staging system for cutaneous melanoma underwent significant revision in 2002. The revised, current AJCC staging system and the TNM classification are detailed in this review.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
